Details for New Drug Application (NDA): 220132
NDA 220132 describes DEFERIPRONE, which is a drug marketed by Hikma, Pharmazone, and Taro, and is included in three NDAs. It is available from four suppliers. Additional details are available on the DEFERIPRONE profile page.
The generic ingredient in DEFERIPRONE is deferiprone. There is one drug master file entry for this compound. Five suppliers are listed for this compound. Additional details are available on the deferiprone profile page.
The generic ingredient in DEFERIPRONE is deferiprone. There is one drug master file entry for this compound. Five suppliers are listed for this compound. Additional details are available on the deferiprone profile page.
Summary for 220132
| Tradename: | DEFERIPRONE |
| Applicant: | Pharmazone |
| Ingredient: | deferiprone |
| Patents: | 0 |
Pharmacology for NDA: 220132
| Mechanism of Action | Iron Chelating Activity |
Suppliers and Packaging for NDA: 220132
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| DEFERIPRONE | deferiprone | TABLET;ORAL | 220132 | ANDA | DR. REDDY'S LABORATORIES, INC. | 75907-348 | 75907-348-50 | 50 TABLET, COATED in 1 BOTTLE (75907-348-50) |
| DEFERIPRONE | deferiprone | TABLET;ORAL | 220132 | ANDA | DR. REDDY'S LABORATORIES, INC. | 75907-349 | 75907-349-01 | 100 TABLET, COATED in 1 BOTTLE (75907-349-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 500MG | ||||
| Approval Date: | Dec 11, 2025 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 1GM | ||||
| Approval Date: | Dec 11, 2025 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
